BioNTech SE (BNTX) Capital Expenditures (2018 - 2025)
BioNTech SE (BNTX) posted Capital Expenditures of -$73.6 million for Q4 2025, down 75.29% sequentially from -$42.0 million in Q3 2025, and down 3.37% YoY from -$76.1 million in Q4 2024.
BioNTech SE (BNTX) Capital Expenditures (2018 - 2025) Analysis & Trends
BioNTech SE has reported Capital Expenditures for 8 years, with the latest figure at -$73.6 million in Q4 2025.
- Quarterly Capital Expenditures fell 3.37% year-over-year to -$73.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$197.6 million (up 36.26% YoY) and the FY2025 annual result came in at $197.8 million, down 35.38% from the prior year.
- Capital Expenditures declined to -$73.6 million in Q4 2025 per BNTX's latest filing, from -$42.0 million in the prior quarter.
- Over five years, Capital Expenditures peaked at -$26.18 in Q1 2021 and troughed at -$139.4 million in Q4 2022.
- A 5-year average of -$65.0 million and a median of -$67.4 million in 2024 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2021 and 2022: Capital Expenditures surged 100.0% in 2021, then tumbled 189090564.66% in 2022.
- Over 5 years, Capital Expenditures stood at -$45.1 million in 2021, then plunged by 209.2% to -$139.4 million in 2022, then jumped by 35.3% to -$90.2 million in 2023, then increased by 21.07% to -$71.2 million in 2024, then dropped by 3.37% to -$73.6 million in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$73.6 million, -$42.0 million, and -$30.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | BioNTech SE | 23.54 Bn | 5.15 Bn | 668.28 Mn | -73.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -73.57 Mn |
| Dec 31, 2025 | -73.57 Mn |
| Sep 30, 2025 | -41.97 Mn |
| Sep 30, 2025 | -41.97 Mn |
| Jun 30, 2025 | -30.68 Mn |
| Jun 30, 2025 | -30.68 Mn |
| Mar 31, 2025 | -51.44 Mn |
| Mar 31, 2025 | -51.44 Mn |
| Dec 31, 2024 | -71.17 Mn |
| Dec 31, 2024 | -71.17 Mn |
| Sep 30, 2024 | -79.95 Mn |
| Sep 30, 2024 | -79.95 Mn |
| Jun 30, 2024 | -95.41 Mn |
| Jun 30, 2024 | -95.41 Mn |
| Mar 31, 2024 | -63.55 Mn |
| Mar 31, 2024 | -63.55 Mn |
| Dec 31, 2023 | -90.16 Mn |
| Dec 31, 2023 | -90.16 Mn |
| Sep 30, 2023 | -57.91 Mn |
| Sep 30, 2023 | -57.91 Mn |